Acromegaly is a hormonal disorder that results from heavy secretion of growth hormones (GH) in the body. The pituitary gland in the brain, secretes GH. In acromegaly, the pituitary produces excessive amounts of GH. Usually the excess GH comes from benign, or noncancerous, tumors on the pituitary. These benign tumors are called adenomas. Acromegaly is one of the rare diseases, which most often diagnosed in the middle-aged adults and affects 5-8 people per 1 lakh people. If the diseases is not treated, it can result in serious illness and premature death. The most serious health consequences of the disease may result into high blood pressure, type 2 diabetes, increased risk of cardiovascular disease, arthritis, and others. The major driving factors for the market are increasing prevalence of acromegaly, changing lifestyle, and increasing genetic incident of genetic diseases. Moreover, increasing prevalence of hormonal diseases, for instance, endocrine diseases, and hypopituitarism, increasing government support and rapid developments in technology have fuelled the growth of the market. On the other hand, surgical costs is high, which ranges from approximately USD 2,800 to USD 9,200, however, when averaged it is less than the cost of medications. Unavailability of precise treatment and high cost of the surgery may restrain the growth of the market.
The global acromegaly market is expected to grow at a CAGR of ~5.2 % during the forecast period 2017-2023.
- Pharmaceutical and Biotechnological Companies
- Medical Devices Industries
- Research and Development (R&D) Companies
- Hospitals and Clinics
- Academic Institutes and Universities
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4429
Acromegaly market is segmented on the basis of types, diagnosis, treatment, and end users.
On the basis of types, the market is segmented into ectopic acromegaly, acromegaly due to growth hormone, and others.
On the basis of diagnosis, the market is segmented into medical imaging, medical laboratory investigations, and others. The medical imaging is further segmented into radiography, magnetic resonance imaging (MRI), nuclear medicine, ultrasound, and others.
On the basis of treatment, the market is segmented into medications, surgery, radiation therapy, and others. The medication is further segmented into somatostatin analogues, dopamine agonists, growth hormone receptor antagonists, and others. The surgery is further segmented into endonasal transphenoidal surgery and transphenoidal surgery.
On the basis of end users, the market is segmented into hospitals, clinics, and others.
The Americas dominates the global acromegaly market owing to the increasing prevalence of acromegaly. According to a Health research funding organization, over 3,000 new cases of acromegaly occurs per year, with a prevalence of about 25,000 acromegaly patients in the US. Increased patient population and high per capita income have driven the growth of the market. Additionally, high healthcare expenditure, strong government support for research & development and the presence of some of the leading players have fuelled the growth of the market in this region.
Europe holds the second position in the global acromegaly market, which is followed by Asia Pacific. The presence of government support and availability of funds for research and development drive the growth of the European market. Asia Pacific is the fastest growing acromegaly market owing to the increasing population, increasing prevalence of hormonal diseases, and rapidly developing healthcare sector.
On the other hand, the Middle East & Africa owns the least share of the global market owing to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.
Some of key the players in the market are Novartis AG (Switzerland), Aegis Therapeutics LLC (US), Chiasma Inc (US), Crinetics Pharmaceuticals Inc (US), Daewoong Pharmaceutical Co Ltd (South Korea), Peptron Inc (South Korea), Silence Therapeutics Plc (UK), Strongbridge Biopharma plc (US), Amryt Pharma plc (UK), Foresee Pharmaceuticals LLC (US), Glide Pharmaceutical Technologies Ltd (US), Ionis Pharmaceuticals Inc (US), Ipsen SA (France)
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4429
Detailed Table of Contents of Acromegaly Market:
1 Report Prologue
2 Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
3 Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
List of Tables and Figures
Table 1 Acromegaly Industry Synopsis, 2017-2023
Table 2 Global Acromegaly Market Estimates And Forecast, 2017-2023, (USD Million)
Table 3 Global Acromegaly Market By Region, 2017-2023, (USD Million)
Table 4 Global Acromegaly Market By Types, 2017-2023, (USD Million)
Table 5 Global Acromegaly Market By Diagnosis, 2017-2023, (USD Million)
Table 6 Global Acromegaly Market By Treatment, 2017-2023, (USD Million)
Table 7 Global Acromegaly Market By End Users, 2017-2023, (USD Million)
Table 8 North America Acromegaly Market By Types, 2017-2023, (USD Million)
Figure 1 Research Process
Figure 2 Segmentation For Global Acromegaly Market
Figure 3 Segmentation Market Dynamics For Global Acromegaly Market
Figure 4 Global Acromegaly Market Share, By Type 2016
Figure 5 Global Acromegaly Market Share, By Diagnosis 2016
Figure 6 Global Acromegaly Market Share, By Treatment 2016
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4429
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312